Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
US7595167B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 11, 2005 |
| Grant date | Sep 29, 2009 |
| Priority date | — |
| Expiry date | May 27, 2026 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2821
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention is directed to a method of diagnosing Alzheimer's disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's disease, monitoring the progression of Alzheimer's disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's disease. The invention is also directed to kits containing reagents for the detection and diagnosis of Alzheimer's disease using the Alzheimer's disease-specific molecular biomarkers disclosed herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.